Pathogenic <i>BRCA</i> Variants as Biomarkers for Risk in Prostate Cancer
Studies have demonstrated that men with Prostate Cancer (PCa) harboring <i>BRCA2/BRCA1</i> genetic aberrations, are more likely to have worse disease and a poorer prognosis. A mutation in <i>BRCA2</i> is known to confer the highest risk of PCa for men (8.6 fold in men ≤65 yea...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
MDPI AG
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/ca595d192acd4bb1bc768ae9dca5dfe3 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Studies have demonstrated that men with Prostate Cancer (PCa) harboring <i>BRCA2/BRCA1</i> genetic aberrations, are more likely to have worse disease and a poorer prognosis. A mutation in <i>BRCA2</i> is known to confer the highest risk of PCa for men (8.6 fold in men ≤65 years) making <i>BRCA</i> genes a conceivable genomic biomarker for risk in PCa. These genes have attracted a lot of research attention however their role in the clinical assessment and treatment of PCa remains complex. Multiple studies have been published examining the relationship between prostate cancer and <i>BRCA</i> mutations. Here <i>BRCA</i> mutations are explored specifically as a biomarker for risk in PCa. It is in this context, we examined the prognostic, clinical and therapeutic role of <i>BRCA2/BRCA1</i> mutations across the evolution of PCa. The impact of the inclusion of <i>BRCA</i> genes on genetic screening will also be outlined. |
|---|